Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data

Background/aim: The incidence of adenoid hypertrophy is 2% 3% in children. Adenoidectomy is a commonly performed procedure in children that may cause complications such as early or late bleeding (4% 5%), recurrence of adenoid tissue (10% 20%), and postoperative respiratory problems (27%). Therefore, medical therapy alternatives to adenoidectomy are important and must be tried before surgery. In this study, we investigated the efficacy of mometasone furoate, montelukast, and a combination of these drugs in pediatric patients with adenoid hypertrophy who were scheduled for reduction with medical therapy after not being recommended for surgery. Materials and methods: The study included 120 children with adenoid hypertrophy aged between 4 and 10 years. The patients were randomized into 4 separate groups, with 30 in each group. Group 1 received 100 µg of mometasone furoate per day, group 2 received 4/5 mg (for age) montelukast per day, and group 3 received mometasone furoate + montelukast. Medical therapy continued for 3 months in the treatment groups. Group 4, which comprised patients with mild symptoms, received no treatment and was the control group. The pre- and posttreatment adenoid tissue ratios in lateral neck radiographs were recorded in the four groups. Results: When radiologic measurements of adenoid-to-air passage were calculated, an improvement of 21.76% was observed in group 1 after treatment. The rate of improvement was 22.51% in group 2. There was a 21.79% reduction in adenoid size in group 3 after 3 monthstreatment and 12.46% in the control group. There were statistically significant differences between pre- and posttreatment values in every single group administered corticosteroids, montelukast, and combined therapy (P < 0.05). Conclusion: According to our results, both montelukast and mometasone furoate therapies were similarly successful in treating adenoid hypertrophy. Combined therapy has no superiority over single-therapy treatment.

PDF

___

1. Bhargava R, Chakravarti A. A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. Am J Otolaryngol 2014; 35: 766-770.
2. Shokouhi F, Jahromi AM, Majidi MR, Salehi M. Montelukast in adenoid hypertrophy: its effect on size and symptoms. Iranian Journal of Otorhinolaryngology 2015; 27: 443-448.
3. Saedi B, Sadeghi M, Mojtahed M, Mahboubi H. Diagnostic efficacy of different methods in the assessment of adenoid hypertrophy. Am J Otolaryngol 2011; 32: 147-151.
4. Shirley WP, Wooley AL, Wiatrak BJ. Pharyngitis and Adenotonsillar Disease In: Cummings Otolaryngology: Head and Neck Surgery. 5th ed. Philadelphia, PA, USA: Elsevier; pp. 2782-2803.
5. Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebocontrolled study. Pediatrics 2012; 130: 575-580.
6. Dayyat E, Serpero LD, Kheirandish-Gozal L, Goldman JL, Snow A, Bhattacharjee R, Gozal D. Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. Chest 2009; 135: 1142-1149.
7. Kaditis AG, Ioannou MG, Chaidas K, Alexopoulos EI, Apostolidou M, Apostolidis T, Koukoulis G, Gourgoulianis K. Cysteinyl leukotriene receptors are expressed by tonsillar T cells of children with obstructive sleep apnea. Chest 2008; 134: 324-331.
8. Goldbart AD, Goldman JL, Li RC, Brittian KR, Tauman R, Gozal D. Differential expression of cysteinyl leukotriene receptors 1 and 2 in tonsils of children with obstructive sleep apnea syndrome or recurrent infection. Chest 2004; 126: 13-18.
9. Berlucchi M, Salsi D, Valetti L, Parrinello G, Nicolai P. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007; 119: 1392-1397.
10. Zhang L, Mendoza-Sassi RA, César JA, Chadha NK. Intranasal corticosteroids for nasal airway obstruction in children with moderate to severe adenoidal hypertrophy. Cochrane Database Syst Rev 2008; 3: CD006286.
11. Chadha NK, Zhang L, Mendoza-Sassi RA, César JA Using nasal steroids to treat nasal obstruction caused by adenoid hypertrophy: does it work? Otolaryngol Head Neck Surg 2009; 140: 139-147.
12. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, Simpson B, Mullin ME, Smith JA. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998; 101: 157-162.
13. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19: 1330-1339.
14. Tracy JM, Demain JG, Hoffman KM, Goetz DW. Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Ann Allergy Asthma Immunol 1998; 80: 198-206.
15. Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007; 30: 317-326.
16. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
17. Minshall E, Ghaffar O, Cameron L, OBrien F, Quinn H, Rowe-Jones J, Davies RJ, Prior A, Lund VJ, Mackay IS et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118: 648-654.
18. Chohan A, Lal A, Chohan K, Chakravarti A, Gomber S. Systematic review and meta-analysis of randomized controlled trials on the role of mometasone in adenoid hypertrophy in children. Int J Pediatr Otorhinolaryngol 2015; 79: 1599-1608.
19. Cassano P, Gelardi M, Cassano M, Fiorella ML, Fiorella R. Denoid tissue rhinopharyngeal obstruction grading based on fiberendoscopic findings: a novel approach to therapeutic management. Int J Pediatr Otorhinolaryngol 2003; 67: 1303- 1309.
20. Cohen D, Konak S. The evaluation of radiographs of the nasopharynx. Clin Otolaryngol Allied Sci 1985; 10: 73-78.
21. Fujioka M, Young LW, Girdany BR. Radiographic evaluation of adenoidal size in children: adenoidal-nasopharyngeal ratio. AJR Am J Roentgenol 1979; 133: 401-404.
22. Dixit Y, Tripathi PS. Community level evaluation of adenoid hypertrophy on the basis of symptom scoring and its X-ray correlation. J Family Med Prim Care 2016; 5: 789-791.
23. Ren YF, Isberg A, Henningsson G. Velopharyngeal incompetence and persistent hypernasality after adenoidectomy in children without palatal defect. Cleft Palate Craniofac J 1995; 32: 476-482.
24. Abdel-Aziz M, Dewidar H, El-Hoshy H, Aziz AA. Treatment of persistent post-adenoidectomy velopharyngeal insufficiency by sphincter pharyngoplasty. Int J Pediatr Otorhinolaryngol 2009; 73: 1329-1333.
25. Yilmaz HB, Celebi S, Sahin-Yilmaz A, Oysu C. The role of mometasone furoate nasal spray in the treatment of adenoidal hypertrophy in the adolescents: a prospective, randomized, cross-over study. Eur Arch Otorhinolaryngol 2013; 270: 2657- 2561.
26. Demain JG, Goetz DW. Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone. Pediatrics 1995; 95: 355-364.
27. Vuralkan E, Saka C, Akin I, Hucumenoglu S, Unal BU, Kuran G, Ocal B. Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps. Ther Adv Respir Dis 2012; 6: 5-10.
28. Martin BG, Andrews CP, van Bavel JH, Hampel FC, Klein KC, Prillaman BA, Faris MA, Philpot EE. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol 2006; 96: 851-857.
29. Friedman BC, Goldman RD. Anti-inflammatory therapy for obstructive sleep apnea in children. Can Fam Physician 2011; 57: 891-893.
30. Kheirandish L, Goldbart AD, Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics 2006; 117: 61-66.